Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive genomic evaluation of advanced and recurrent breast cancer patients for tailored precision treatments.

BMC cancer - 16 Jan 2024

Ido Mirai, Fujii Kimihito, Mishima Hideyuki, Kubo Akihito, Saito Masayuki, Banno Hirona, Ito Yukie, Goto Manami, Ando Takahito, Mouri Yukako, Kousaka Junko, Imai Tsuneo, Nakano Shogo

Abstract excerpt

AIM: The aim of this study was to investigate genetic alterations within breast cancer in the setting of recurrent or de novo stage IV disease. PATIENTS AND METHODS: This study included 22 patients with recurrent breast cancer (n = 19) and inoperable de novo stage IV breast cancer (n = 3). For next generation sequencing, FoundationOneCDx (F1CDx) (Foundation Medicine Inc., Cambridge, MA, USA) was performed in 21...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomics

Share to High-Throughput Nucleotide Sequencing

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Phosphatidylinositol 3-Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 38229073
DOI: 10.1186/s12885-023-11442-9
PMCID: PMC10790483

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive genomic evaluation of advanced and recurrent breast cancer patients for tailored precision treatments.PMID 38229073Read ↗

Comprehensive genomic evaluation of advanced and recurrent breast cancer patients for tailored precision treatmentsSemantic proximity Read ↗

Concordance of genomic alterations between primary and recurrent breast cancer.Semantic proximity Read ↗

Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.Semantic proximity Read ↗

Genetic alterations and their association with clinicopathologic characteristics in advanced breast carcinomas: focusing on clinically actionable genetic alterations.Semantic proximity Read ↗

Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesionsSemantic proximity Read ↗

Clinical Genomic Profiling to Identify Actionable Alterations for Very Early Relapsed Triple-Negative Breast Cancer Patients in the Chinese PopulationSemantic proximity Read ↗

Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.Semantic proximity Read ↗

Comparative Genomic Profiling of Second Breast Cancers following First Ipsilateral Hormone Receptor-Positive Breast Cancers.Semantic proximity Read ↗

Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions.Semantic proximity Read ↗

Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.Semantic proximity Read ↗

Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial.Semantic proximity Read ↗

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigmsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.